Investors and Media

San Francisco, Calif. - December 1, 2008

FibroGen, Inc., today announced the appointment of Frank H. Valone, M.D., as Chief Medical Officer. Dr. Valone brings more than 14 years of biotechnology industry experience in the leadership of clinical and preclinical development, medical and regulatory affairs, and quality assurance and control.

Dr. Valone was most recently Senior Vice President of Medical Affairs at Bayhill Therapeutics where he was responsible for clinical, regulatory, quality and nonclinical toxicology/safety aspects related to the development of Bayhill's investigational therapies. Prior to Bayhill, Dr. Valone was Executive Vice President, Clinical Development and Regulatory Affairs of Titan Pharmaceuticals, Inc., and prior to that, he was Senior Vice President, Medical and Regulatory Affairs at Dendreon Corporation where he oversaw the advancement of the company's lead product for prostate cancer, Provenge® (sipuleucel-T), from phase 1 into phase 3 clinical testing.

"With several ongoing clinical programs for our investigational small molecule and antibody therapies, Frank's proven experience and success will be an important asset to FibroGen," said Thomas B. Neff, Chief Executive Officer of FibroGen. "We look forward to his contributions in helping us to advance our compounds through clinical development and on to approval and commercialization."

Dr. Valone received a B.A. from Hamilton College and an M.D. from Harvard Medical School. Prior to his career in the biotechnology industry, Dr. Valone held various academic positions including Adjunct Professor of Medicine at Dartmouth-Hitchcock Medical Center, Associate Professor of Medicine at the University of California in San Francisco, and Clinical Associate Professor in the Department of Medicine at Stanford University.

About FibroGen
FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, conditions associated with tissue damage or injury, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen's proprietary cosmetic dermal filler and biomaterials supply business.

For more information about FibroGen, Inc., please visit www.fibrogen.com.

Contact:
Laura Hansen, Ph.D., Director, Corporate Communications 415-978-1433 or [email protected]